Genomic architecture and prediction of censored time-to-event phenotypes with a Bayesian genome-wide analysis - Ojavee, Sven E.; Kousathanas, Athanasios; Banos, Daniel Trejo; Orliac, Etienne J.; Patxot, Marion; Läll, Kristi; Mägi, Reedik; Fischer, Krista; Kutalik, Zoltan; Robinson, Matthew R. (medRxiv, 2021)
Here, we develop a Bayesian approach (BayesW) that provides probabilistic inference of the genetic architecture of age-at-diagnosis of disease and time-to-event phenotypes. We show in extensive simulation work that our method provides insight into genetic effects underlying disease progression, achieving a greater number of discoveries, better model performance and improved genomic prediction as compared to other approaches. We develop a hybrid-parallel sampling scheme facilitating age-at-onset analyses in large-scale biobank data. In the UK Biobank, we find evidence for an infinitesimal contribution of many thousands of common genomic regions to variation in the onset of common complex disorders of high blood pressure (HBP), cardiac disease (CAD), and type-2 diabetes (T2D), and for the genetic basis of age-at-onset reflecting the underlying genetic liability to disease. In contrast, while age-at-menopause and age-at-menarche are highly polygenic, we find higher variance contributed by low frequency variants. We find 291 LD-independent regions for age-at-menarche with ≥ 95% posterior inclusion probability of contributing 0.001% to the genetic variance, 176 regions for age-at-menopause, 441 regions for age-at-diagnosis of HBP, 67 regions for CAD, and 108 regions for T2D. Genomic prediction into the Estonian Genome Centre data shows that BayesW gives higher prediction accuracy than other approaches.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by an SNSF Eccellenza Grant to MRR (PCEGP3-181181), and by core funding from the Institute of Science and Technology Austria and the University of Lausanne; the work of KF was supported by the grant PUT1665 by the Estonian Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Canton Vaud ethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis project uses UK Biobank data under project 35520. The Estonian Biobank data are available upon request from the cohort authors with appropriate research agreements.